Related Experiment Video
Updated: May 2, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
Clostridium difficile infection among children across diverse US geographic locations
Joyanna M Wendt1, Jessica A Cohen, Yi Mu
1Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases.
Insights
Clostridium difficile infection (CDI) is common in young children, with similar disease severity across age groups. Prioritizing prevention efforts to reduce unnecessary antibiotic use in outpatient settings is crucial for reducing pediatric CDI rates.
Area of Science:
- Pediatric Infectious Diseases
- Epidemiology
- Microbiology
Background:
- Clostridium difficile infection (CDI) epidemiology in children, especially those under 3 years, is not well understood.
- Colonization with C. difficile is common in young children, but its role in causing infection is uncertain.
Purpose of the Study:
- To describe the incidence, clinical presentation, and outcomes of pediatric CDI.
- To analyze CDI data across different pediatric age groups.
Main Methods:
- Utilized active population- and laboratory-based CDI surveillance data from 2010-2011 in 10 US areas.
- Identified pediatric CDI cases (ages 1-17) and categorized them into community-associated (CA) and healthcare-associated.
- Compared demographic, exposure, and clinical data across four age groups: 1 year, 2-3 years, 4-9 years, and 10-17 years.
Main Results:
- Of 944 pediatric CDI cases, 71% were community-associated.
- The highest CDI incidence was observed in 1-year-olds (66.3 per 100,000).
- Diarrhea and severe disease proportions were similar across age groups, with no reported deaths.
Conclusions:
- The consistent disease severity suggests C. difficile plays a significant role in CDI among young children.
- Prevention strategies should focus on reducing unnecessary antibiotic prescriptions in outpatient pediatric care.
Objective:
Little is known about the epidemiology of Clostridium difficile infection (CDI) among children, particularly children ≤3 years of age in whom colonization is common but pathogenicity uncertain. We sought to describe pediatric CDI incidence, clinical presentation, and outcomes across age groups.
Methods:
Data from an active population- and laboratory-based CDI surveillance in 10 US geographic areas during 2010-2011 were used to identify cases (ie, residents with C difficile-positive stool without a positive test in the previous 8 weeks). Community-associated (CA) cases had stool collected as outpatients or ≤3 days after hospital admission and no overnight health care facility stay in the previous 12 weeks. A convenience sample of CA cases were interviewed. Demographic, exposure, and clinical data for cases aged 1 to 17 years were compared across 4 age groups: 1 year, 2 to 3 years, 4 to 9 years, and 10 to 17 years.
Results:
Of 944 pediatric CDI cases identified, 71% were CA. CDI incidence per 100,000 children was highest among 1-year-old (66.3) and white (23.9) cases. The proportion of cases with documented diarrhea (72%) or severe disease (8%) was similar across age groups; no cases died. Among the 84 cases interviewed who reported diarrhea on the day of stool collection, 73% received antibiotics during the previous 12 weeks.
Conclusions:
Similar disease severity across age groups suggests an etiologic role for C difficile in the high rates of CDI observed in younger children. Prevention efforts to reduce unnecessary antimicrobial use among young children in outpatient settings should be prioritized.
Related Concept Videos
Bacterial Gastroenteritis
Investigation of Disease Outbreaks
Diphtheria
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Clinical Significance of Antibiotic Resistance
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.

